Vandria: Series B Funding for Alzheimer’s Phase II Trial | Firstword Pharma

by Archynetys Health Desk
  1. Vandria seeks series B funding to advance Alzheimer’s candidate into Phase II  FirstWord Pharma
  2. Swiss biotech plots Series B raise to advance Alzheimer’s drug into Phase 2  Endpoints News
  3. Vandria Reports First Human Data for Mitophagy-Based Alzheimer’s Drug VNA-318  geneonline.com

Related Posts

Leave a Comment